doi: 10.1161/CIRCULATIONAHA.105.576017
(Circulation. 2005;112:2951-2958.)
© 2005 American Heart Association, Inc.
Molecular Cardiology |
Extracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heart
From the Department of Medicine, Division of Cardiology (E.M.), Department of Pathology (M.A.L., C.E.M.), University of Washington School of Medicine, Seattle, and Department of Pathology (J.E.S.), Washington University School of Medicine, St Louis, Mo. Dr Saffitz is currently at the Department of Pathology, Harvard Medical School, Boston, Mass.
Correspondence to Charles E. Murry, MD, PhD, University of Washington Center for Cardiovascular Biology and Regenerative Medicine, 815 Mercer St, Room 453, Seattle, WA 98109. E-mail murry{at}u.washington.edu
Received June 10, 2005; de novo received July 14, 2005; revision received August 17, 2005; accepted August 22, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Extracardiac progenitor cells are capable of repopulating cardiomyocytes at very low levels in the human heart after injury. Here, we explored the extent of endothelial, smooth muscle, and Schwann cell chimerism in patients with sex-mismatched (female-to-male) heart transplants.
Methods and Results— Autopsy specimens from 5 patients and endomyocardial biopsies from 7 patients were used for this study. Endothelial, vascular smooth muscle, and Schwann cells were stained with antibodies against CD31 or Ulex europaeus lectin, smooth muscle 
-actin, and S-100, respectively, and the Y chromosome was identified with in situ hybridization. Biopsy specimens from 1, 4, 6, and 12 months and 5 and 10 years after heart transplantation were evaluated. Y-positive cells were counted by conventional bright-field microscopy and confirmed by confocal microscopy. Endothelial cells showed the highest degree of chimerism, averaging 24.3±8.2% from extracardiac sources. Schwann cells showed the next highest chimerism, averaging 11.2±2.1%; vascular smooth muscle cells averaged 3.4±1.8%. All 3 cell types showed substantially higher chimerism than we previously observed for cardiomyocytes (0.04±0.05%). Endothelial chimerism was much higher in the microcirculation than in larger vessels. Analysis of serial endomyocardial biopsies revealed that high levels of endothelial chimerism occurred as early as 1 month after transplantation (22±6.6%) with no significant increases even up to 10 years after cardiac transplantation.
Conclusions— Extracardiac progenitor cells are capable of repopulating most major cell types in the heart, but they do so with varying frequency. The signals for endothelial progenitor recruitment occur early and could relate to injury during allograft harvest or transplantation. The high degree of endothelial chimerism may have immune implications such as for myocardial rejection or graft vasculopathy.
Key Words: endothelium • pathology • stem cells • transplantation • Y chromosome
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The heart has marginal ability to regenerate. As a consequence, it heals after infarction by scar formation and wall thinning in the infarct region, compensatory hypertrophy in the viable myocardial regions, and eventual dilation.1–5 In more severe cases, this process translates into clinical heart failure and marked functional decline. Recently, there is growing evidence that extracardiac progenitor cells may contribute to heart repair after injury. Although first described in animal models,6–12 several groups, including our own, have shown similar derivation of different cell types from progenitor cells in humans.13–17
One way to trace the lineage of these progenitor cells in humans is to study sex-mismatched heart transplants.18 When a female heart is transplanted into a male patient, in situ hybridization with a Y-chromosome probe allows identification of extracardiac cells in the female allograft. Using this approach, we have recently shown that 0.04% of cardiomyocytes in the transplant heart are extracardiac derived and are recipient in origin.13
The goal of this study was to determine whether extracardiac progenitor cells are capable of repopulating multiple other cell types in the human transplanted heart. We also sought to determine the time course of endothelial cell chimerism to shed more light on its mechanism and its influence on clinical outcome.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Specimen Selection
This study was approved by the Institutional Review boards of the University of Washington in Seattle and Washington University School of Medicine in St Louis. Five autopsy cases were used to investigate the extent of chimerism in the transplanted heart. These specimens were identified as having sex-mismatched transplants after review of the Washington University School of Medicine pathology files. For the endothelial chimerism time course study, we identified 7 male patients with female cardiac allograft transplants who are still alive and who had serial endomyocardial biopsies from 1 month to 10 years after transplantation. For comparison of autopsy and biopsy patients in the time course evaluation, 3 of the 5 autopsy patients (patients 1, 2, and 3) were included because they lived from a range of 19 to 50 months after transplantation. Because patients 4 and 5 did not survive past 12 months, their specimens were not included in the time course study. Five female and 4 male subjects who did not undergo heart transplantation were used as negative and positive controls, respectively.
Immunohistochemistry and In Situ Hybridization
We prepared 5-µm sections from formalin-fixed, paraffin-embedded tissue blocks from both autopsy and biopsy specimens and subjected them to immunohistochemical staining and in situ hybridization techniques as previously described.13 In brief, these sections were deparaffinized and quenched for endogenous peroxidase activity (15 minutes in 100% methanol and 3% hydrogen peroxide). These sections were then blocked with 1.5% normal horse serum (Vector) and incubated overnight with primary antibodies to smooth -actin (smooth muscle cells, mouse monoclonal, DAKO) and S-100 (Schwann cells/peripheral nerve, rabbit polyclonal, DAKO). For endothelial cells, biotinylated Ulex europaeus lectin (Vector) was used for the biopsy specimens, and CD31 was used for the autopsy specimens. Pilot studies showed that the autopsy fixation protocol was not consistently compatible with Ulex staining, and many of the biopsy specimens, in which the endothelium stained well with Ulex, did not stain uniformly with CD31. Because 2 different endothelial markers were used in this study as a result of fixation obstacles, we confirmed that the percentage of endothelial chimerism did not vary between Ulex and CD31 staining in the biopsy specimens that stained for both (data not shown). As shown in Figure I of the online-only Data Supplement (found at http://circ.ahajournals.org/cgi/content/full/112/19/2951/DC1), Ulex staining was specific to endothelial cells and did not label leukocytes. Microscopic fields of interest were acquired via digital photography (Spot Diagnostic instruments). Primary antibodies were visualized by avidin-biotin complex alkaline phosphatase after incubation with appropriate secondary antibodies. Chromagen Vector Red (Vector) was used to visualize the specific antibody or lectin.
After immunostaining was complete, Y-chromosome in situ hybridization was performed on the same tissue sections. A digoxigenin-labeled probe was prepared by random priming and hybridized to a highly repetitive target sequence in the human Y chromosome as previously described.13 After overnight hybridization and stringent washes, the probe was visualized with a peroxidase-conjugated anti-digoxigenin antibody (Roche) and diaminobenzidine as substrate. Slides were counterstained with hematoxylin with Scott’s blue.
To confirm the in situ hybridization and immunohistochemical data, 3 of the autopsy patients were studied by confocal fluorescent microscopy. The sections were deparaffinized and treated with 2x standard sodium citrate at 80°C for 10 minutes, followed by antigen retrieval (pH 4.5) for 20 minutes. The sections were then subjected to proteinase K treatment at 37°C for 15 minutes and placed in denaturation solution (2x standard saline citrate, 70% formamide) at 73°C for 5 minutes. The sections were then incubated with the probe (CEP Y SG Sat III DNA probe, Vysis) for 10 minutes at 75°C and overnight at 37°C. Slides were then washed with 2x standard saline citrate. Primary antibodies to endothelial, smooth muscle, and Schwann cells were applied in a manner similar to that of the standard immunohistochemical technique mentioned above, incubated overnight, and labeled with Alexa Red 598 secondary antibody (Molecular Probes) to identify the specific cell type. The nucleus was counterstained with DAPI II (Vysis).
Cell Counting
For conventional bright-field microscopy, rigorous criteria were used to determine whether a Y-chromosome signal was indeed within the nucleus of the cell and whether that nucleus resided within a labeled cell population. For all cell types counted, the nuclei had to be completely surrounded by the cell type–specific immunostaining product. In addition, the cells had to be in a normal morphological context within the tissue. Staining for Y chromosome was regarded as positive if a punctate, dark-brown signal was present within a given blue-stained nucleus and in the same focal plane. Y-chromosome signals frequently showed an eccentric localization within the nucleus. The density of nuclei per section was determined by enumerating 30 square fields of 104 µm2 each with a gridded ocular reticule. Y-positive cells were manually counted for all cell types and all nuclei under each gridded ocular reticule by raster scanning the entire slide at x100 objective. The percent of each cell type that was Y positive was calculated by dividing the total number of Y-positive cells counted over the total number of nuclei counted for each specimen and for each cell type. All Y chromosome–positive counts were corrected for false negatives determined by hybridization efficiency, which was defined as Y chromosome–positive nuclei divided by total nuclei counted in male control subjects. The hybridization efficiency was 47.7±2.7% for endothelial cells, 45.4±1.3% for smooth muscle cells, and 29.5±8.4% for Schwann cells. The corrected mean±SD percentage incorporates this false-negative correction.
For cell counting with confocal microscopy, 30 to 40 visual fields from each section were obtained by use of the Leica model TCS-SP1-MP confocal microscope under a x40 oil objective. The range of wavelength detected for each fluoroprobe is as follows: FITC channel, between 498 and 600 nm; Alexa Red channel, between 580 and 742 nm; and DAPI channel, between 395 and 560 nm. The number of nuclei counted per section ranged from 95 to 1197. Cells were considered positive if the Y signal was contained in the nucleus and completely surrounded by cytoplasm for each cell type.
The hybridization efficiency for fluorescent in situ hybridization (FISH) using male control subjects was as follows: 26.9±2.6% for endothelial cells, 24.4±0.57% for smooth muscle cells, and 27.2±3.11% for Schwann cells. Possible explanations for the lower hybridization efficiency of FISH protocol include the lower time of denaturation at high temperature during the hybridization step, the thinner optical section used for confocal analysis compared with the 5-µm section for conventional microscopy, and a lower sensitivity of the fluorescent Y probe.
For quantifying endothelial chimerism in the autopsy specimens, the specimens were divided into epicardial and intramyocardial compartments and endocardium. In the epicardial compartment, separate counts were obtained for small (defined in this case as <250 µm in diameter) and large (>250 µm) vessels; the latter category was further subdivided histologically into arteries and veins. In the intramyocardial compartment, vessels were subdivided as large vessels (again defined as >250 µm), intramyocardial arterioles (defined as small, 30- to 100-µm arteries with definite circumscribed smooth muscle), and all other small vessels (defined as <30 µm in diameter). Of note, the last category of small vessels was composed predominantly of capillaries (defined as 7 to 8 µm in diameter). Smooth muscle cell chimerism was quantified in the autopsy specimens with the same categories of vessel localization and size.
For the time course study, biopsy specimens from 7 patients were obtained from time points of 1, 4, 6, and 12 months and 5 and 10 years after cardiac transplantation. For the 3 autopsy patients whose biopsy specimens were used for the time course study, we looked at specimens from 1, 4, 6, and 12 months and their last biopsies after cardiac transplantation.
Statistical Analysis
All data are presented as the mean±SD percentage. Calculations were made with the InStat statistical program. Comparisons of chimerism in vessels by location and size were made by ANOVA. Values of P<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
For the first phase of our study, male autopsy patients who underwent a female allograft heart transplantation were investigated so that we could identify recipient-derived cells using Y-chromosome in situ hybridization. The age at autopsy ranged from 23 to 62 years, and the transplantation–death interval ranged from 9 to 50 months (Table 1). Patients 1 through 3 were included in the study for time course measurements of endothelial chimerism because they survived at least 19 months to as long as 50 months after transplantation. The biopsy specimens used for the time course analysis were obtained from 7 male post–cardiac transplantation patients with female allografts who continue to remain alive as of this writing (Table 2). The most common reason for transplantation was ischemic heart disease, and mild coronary atherosclerosis was present in all patients on their most current angiogram except for patients 6 and 7, who demonstrated moderate narrowing.
|
|
Extent of Chimerism in Autopsy Specimens
In contrast to our earlier study,13 which detected 0.04% cardiomyocytes repopulated from extracardiac cells, there was much greater chimerism in other cell types of the heart, namely endothelial, vascular smooth muscle, and Schwann cells. The vascular samples available for study did not have significant transplant arteriopathy. For endothelial cells, an overall mean of 24.3±8.2% was derived from extracardiac progenitors in the autopsy cases (Table 3); this measurement correlated well with confocal microscopy (31.2±12.8%). Representative examples are shown in Figures 1A, 1B, 2A, and 2 
B. These figures show multiple Y-positive endothelial cells in a single vascular cross section, a common anatomic finding. The endothelial cells, however, were not distributed uniformly throughout the vasculature. Large coronary arteries and veins (>250-µm diameter) had fewer extracardiac-derived endothelial cells, ranging from 4.4% to 11.6% (Table 3). In contrast, coronary microvessels (
100-µm diameter) had endothelial chimerism that ranged from 23.1% to 36.3%. No systematic differences in chimerism were noted between arteries and veins regardless of size. The endocardial endothelium averaged 22.8% extracardiac derived.
|
|
|
Next, we studied chimerism in vascular smooth muscle cells from the autopsy specimens. Smooth muscle chimerism was &7-fold less common than that of endothelial cells, with an overall corrected mean of 3.4±1.8% of extracardiac origin (Table 4 and Figure 1C and 1D). We searched for differences in smooth muscle cell chimerism in microvessels versus large vessels, arteries versus veins, and location on the epicardial surface versus within the myocardium. No significant difference in smooth muscle cell chimerism was noted (Table 4). Using confocal microscopy, we counted modestly higher levels of smooth muscle cell chimerism (5.9±1.2%), although we think these values fall within the error margin of the 2 approaches.
|
Our final cell population of interest was the peripheral nerve Schwann cell. Using S-100 to identify these cells, we observed a corrected mean of 11.2±2.1% Schwann cells derived from outside the heart (Figure 1E and 1F). This corrected mean was comparable to confocal microscopy (14.1±2.9%; Figure 2E and 2F). The Y-positive Schwann cells were typically isolated (Figures 1E and 2
F) or occasionally clustered in small groups (Figure 1F). We did not observe nerve segments with coherent labeling comparable to male control hearts.
Time Course of Endothelial Chimerism
Endomyocardial biopsies are performed frequently during the first year after transplantation to monitor for rejection and at least annually thereafter. This allows an opportunity to study the temporal development of endothelial chimerism. We hypothesized that chimerization would evolve gradually, possibly taking months or even years to reach its maximal extent. To our surprise, biopsies taken as early as 1 month showed high levels of endothelial chimerism (21.7±6.6%; Table 5 and Figure 3). Although there was some variation in the extent of chimerism within a given patient from biopsy to biopsy, there was no consistent increase or decrease over time. Indeed, biopsies from patients at 10 years after transplantation revealed 19.2±8.8% of endothelial cells to be of extracardiac origin (Table 5). Thus, endothelial chimerization appears to be established at high levels within the first month after transplantation and is stable thereafter.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, we have demonstrated that extracardiac progenitor cells are capable of repopulating most cell types in the human heart. We found that the frequency of chimerism varies widely by cell type in the following order: endothelial cells (24.3%) > Schwann cells (11.2%) > smooth muscle cells (3.4%)
cardiomyocytes (0.04%) (Figure 4). Comparable values were obtained with a FISH and confocal microscopic technique. Endothelial cell chimerism has a predilection for small epicardial and intramyocardial vessels, which had a notable 3- to 5-fold-greater chimerism than their larger counterparts. Surprisingly, the degree of endothelial cell chimerism plateaus as early as 1 month and maintains that level even 10 years after transplantation. It should be noted that multiple studies in experimental animals have demonstrated that circulating progenitor cells are capable of repopulating cells in the heart, possibly contributing to coronary atherosclerosis, transplant arteriopathy, and angiogenesis. Although a detailed review of these animal studies is beyond the scope of this article, we refer interested readers to the recent excellent review by Hillebrands et al.19
|
Although our study addressed most cell populations in the heart, we were, unfortunately, unable to study chimerism in fibroblasts. Despite many attempts, we could not identify an antibody that marks this cell population selectively in formalin-fixed, paraffin-embedded tissue. We would expect, however, that fibroblast chimerism might play an important role in the cardiac reparative process because fibroblasts produce the extracellular matrix and scar tissue of the heart.
Endothelial Chimerism in Human Transplants
Quaini et al14 studied the degree of chimerism in 8 sex-mismatched transplant recipients using fluorescent Y probe to detect cells from recipient origin. Like us, they restricted their analyses to structurally normal coronary vessels. Unlike the present study, however, they counted the frequency of Y-positive vessels (defined as 30% or more Y-positive cells) rather than Y-positive cells. They reported significant levels of chimerism in capillaries (14% extracardiac derived) and arterioles (21% to 50% extracardiac-derived endothelial cells in vessels having at least 30% Y-positive smooth muscle cells). Despite these methodological differences, their findings seem to be in the same range as the present study. Simper et al20 investigated the levels of circulating endothelial cells and endothelial progenitor cells in 5 female-to-male heart transplant patients who had angiographic evidence for transplant atherosclerosis. In that study, comparison of endothelial cell chimerism between diseased and nondiseased segments of the coronary arteries also was performed with FISH. In the diseased segments, chimerism of luminal endothelium ranged from 1% to 24%, whereas chimerism of adventitial microvascular endothelium ranged from 1% to 11%. If we adjust these data for their hybridization efficiency (41%), chimerism more than doubles and hence overlaps significantly with our own data set. Surprisingly, when these investigators performed a smaller subgroup analysis, they found that structurally normal regions of arteries (with disease elsewhere) showed only 0.2% endothelial chimerism. This is significantly lower than what we observed in nondiseased segments. Finally, Hocht-Zeisberg et al21 compared endothelial chimerism in gender-mismatched transplants with (n=5) and without (n=9) myocardial infarction. They reported >50-fold-increased endothelial chimerism in the infarcted hearts, although their baseline levels of chimerism (0.01%) were substantially lower than what we observed in our patients. The reason for this difference is not entirely clear. One contributing factor may be their use of von Willebrand factor to define endothelium. Von Willebrand factor is heterogeneously expressed in endothelium, with a predilection toward large vessel endothelium (where we observed lower chimerism). In our hands, both Ulex europaeus and CD31 afford more uniform staining of macrovascular and microvascular endothelium. Hocht-Zeisberg et al21 proposed that conventional microscopy overestimates the degree of chimerism resulting from the overlap of cells in which a Y-positive leukocyte nucleus might be mistaken for that of a resident cell. We minimized this artifact by using strict criteria to assign nuclei to cells or in situ signals to nuclei and showed that these criteria gave data comparable to those obtained by confocal microscopy.
Smooth Muscle Cell Chimerism in Human Transplants
Recently, Glaser et al16 reported a range of 0.8% to 5.6% recipient-derived smooth muscle cells in coronary arteries (corrected range, 2.3% to 16%) from 6 male heart transplant recipients with various degrees of transplant vasculopathy who received a female donor heart. These data are comparable to our observation of 3.4% recipient-derived smooth muscle cells derived by bright-field microscopy and 5.9% by confocal microscopy. Quaini et al14 also studied smooth muscle chimerism in gender-mismatched hearts, although like their endothelial data, they counted the frequency of Y-positive arterioles (defined as containing 30% Y-positive smooth muscle cells) rather than Y-positive cells. They reported that 10% of arterioles were Y positive, which, although not directly comparable, seems within the range of our approach.
A recent study by Caplice et al22 suggests that a source of these smooth muscle progenitor cells may be bone marrow. Studying gender-mismatched bone marrow transplant patients, they reported that 9.4% of smooth muscle cells in atherosclerotic coronary intimas were marrow derived versus 0.1% in nondiseased intimas. This relatively low chimerism in nondiseased segments after bone marrow transplantation versus relatively high chimerism (3.5%) after cardiac transplantation suggests that vessels in the allograft may be subject to injury and repair cycles not present after bone marrow transplantation. For example, ischemic injury in the peritransplantation period or more chronic immune injury may recruit progenitor cells to participate in vascular repair.
Schwann Cell Chimerism
Cardiac denervation occurs after transplantation, and the consequences include diminished exercise capacity as a result of chronotropic incompetence and lack of sympathetic and parasympathetic regulation. Reinnervation has been reported in some patients, as evidenced by improvement in hemodynamic response to exercise and the presence of chest pain during activity or with cardiac biopsies.23–27 Our finding that 11.6% of Schwann cells arise from extracardiac progenitors is, to the best of our knowledge, the first structural evidence for cardiac reinnervation after transplantation. Interestingly, the Y-positive Schwann cells were typically isolated or in small cell clusters rather than extending contiguously along a fiber tract. This suggests that the Y-positive Schwann cells did not arise by direct extension from the transected host nerve fibers. Their isolated distribution is more consistent with seeding from a circulating source.
Clinical Implication of Chimerism
Hematopoietic chimerism has been proposed as a method for graft protection and as a method to ameliorate allograft vasculopathy.28–34 Orloff et al28 created bone marrow chimeras using marrow from Lewis rats to F-344 rats and performed heterotopic heart transplantation. These animals demonstrated tolerance for 120 days after transplantation and a lack of graft vasculopathy. Control groups without marrow chimerism developed rejection despite cyclosporine and consistently developed graft vasculopathy. Similarly, Shirwan et al33 induced donor-specific tolerance to cardiac allografts by injecting donor blood or T or B cells 7 days before transplantation and found graft acceptance by recipients. We hypothesize that, similar to hematopoietic chimerism, high levels of endothelial cell chimerism may have a protective effect and potentially minimize graft failure. Additional studies are required to understand the mechanism, regulation, and ultimately the long-term consequences of chimerism and assist in predicting clinical outcome. If we could learn to control endothelial chimerism, it might be possible to delay or prevent transplant arteriopathy, which is the most common cause for failure of transplanted solid organs.
|
Acknowledgments |
|---|
These studies for supported in part by NIH grants R01 HL61553, P01 HL03174, and R24HL64387 (to Dr Murry) and NRSA grant HL 068400-02 and UW Bioengineering Training grant T32HL07403 (to Dr Minami). We thank Veronica Muskheli and Sarah Dupras for their expert technical assistance.
|
Footnotes |
|---|
*Drs Minami and Laflamme contributed equally to this work.
The online-only Data Supplement can be found at http://circ.ahajournals.org/cgi/content/full/112/19/2951/DC1.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Roberts CS, Maclean D, Maroko P, Kloner RA. Early and late remodeling of the left ventricle after acute myocardial infarction. Am J Cardiol. 1984; 54: 407–410.[CrossRef][Medline] [Order article via Infotrieve]
2. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986; 74: 693–702.
3. Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after myocardial infarction. Circulation. 1987; 75 (suppl IV): IV-93–IV-7.[Medline] [Order article via Infotrieve]
4. Pfeffer JM, Pfeffer MA. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med. 1988; 84: 37–44.[Medline] [Order article via Infotrieve]
5. Hochman JS, Bulkley BH. Expansion of acute myocardial infarction: an experimental study. Circulation. 1982; 65: 1446–1450.
6. Bittner RE, Schofer C, Weipoltshammer K, Ivanova S, Streubel B, Hauser E, Freilinger M, Hoger H, Elbe-Burger A, Wachtler F. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl). 1999; 199: 391–396.[CrossRef][Medline] [Order article via Infotrieve]
7. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001; 107: 1395–1402.[CrossRef][Medline] [Order article via Infotrieve]
8. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701–705.[CrossRef][Medline] [Order article via Infotrieve]
9. Hillebrands J, van den Hurk BM, Klatter FA, Popa ER, Nieuwenhuis P, Rozing J. Recipient origin of neointimal vascular smooth muscle cells in cardiac allografts with transplant arteriosclerosis. J Heart Lung Transplant. 2000; 19: 1183–1192.[CrossRef][Medline] [Order article via Infotrieve]
10. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med. 2001; 7: 382–383.[CrossRef][Medline] [Order article via Infotrieve]
11. Wang JS, Shum-Tim D, Chedrawy E, Chiu RC. The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg. 2001; 122: 699–705.
12. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403–409.[CrossRef][Medline] [Order article via Infotrieve]
13. Laflamme MA, Myerson D, Saffitz JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res. 2002; 90: 634–640.
14. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Chimerism of the transplanted heart. N Engl J Med. 2002; 346: 5–15.
15. Deb A, Wang S, Skelding KA, Miller D, Simper D, Caplice NM. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation. 2003; 107: 1247–1249.
16. Glaser R, Lu MM, Narula N, Epstein JA. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation. 2002; 106: 17–19.
17. Fogt F, Beyser KH, Poremba C, Zimmerman RL, Ruschoff J. Evaluation of host stem cell-derived cardiac myocytes in consecutive biopsies in long-term cardiac transplant patients. J Heart Lung Transplant. 2003; 22: 1314–1317.[CrossRef][Medline] [Order article via Infotrieve]
18. Hruban RH, Long PP, Perlman EJ, Hutchins GM, Baumgartner WA, Baughman KL, Griffin CA. Fluorescence in situ hybridization for the Y-chromosome can be used to detect cells of recipient origin in allografted hearts following cardiac transplantation. Am J Pathol. 1993; 142: 975–980.[Abstract]
19. Hillebrands JL, Klatter FA, Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol. 2003; 23: 380–387.
20. Simper D, Wang S, Deb A, Holmes D, McGregor C, Frantz R, Kushwaha SS, Caplice NM. Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation. 2003; 108: 143–149.
21. Hocht-Zeisberg E, Kahnert H, Guan K, Wulf G, Hemmerlein B, Schlott T, Tenderich G, Korfer R, Raute-Kreinsen U, Hasenfuss G. Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. Eur Heart J. 2004; 25: 749–758.
22. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003; 100: 4754–4759.
23. Givertz MM, Hartley LH, Colucci WS. Long-term sequential changes in exercise capacity and chronotropic responsiveness after cardiac transplantation. Circulation. 1997; 96: 232–237.
24. Schwaiblmair M, von Scheidt W, Uberfuhr P, Ziegler S, Schwaiger M, Reichart B, Vogelmeier C. Functional significance of cardiac reinnervation in heart transplant recipients. J Heart Lung Transplant. 1999; 18: 838–845.[CrossRef][Medline] [Order article via Infotrieve]
25. Murphy DA, Thompson GW, Ardell JL, McCraty R, Stevenson RS, Sangalang VE, Cardinal R, Wilkinson M, Craig S, Smith FM, Kingma JG, Armour JA. The heart reinnervates after transplantation. Ann Thorac Surg. 2000; 69: 1769–1781.
26. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001; 345: 731–738.
27. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients: evidence of sensory reinnervation after cardiac transplantation. N Engl J Med. 1991; 324: 1791–1794.[Medline] [Order article via Infotrieve]
28. Orloff MS, DeMara EM, Coppage ML, Leong N, Fallon MA, Sickel J, Zuo XJ, Prehn J, Jordan SC. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation. 1995; 59: 282–288.[Medline] [Order article via Infotrieve]
29. Orloff SL, Yin Q, Corless CL, Orloff MS, Rabkin JM, Wagner CR. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation. 2000; 69: 1295–1303.[CrossRef][Medline] [Order article via Infotrieve]
30. McDaniel DO, Naftilan J, Hulvey K, Shaneyfelt S, Lemons JA, Lagoo-Deenadayalan S, Hudson S, Diethelm AG, Barber WH. Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation. 1994; 57: 852–856.[Medline] [Order article via Infotrieve]
31. Kawai T, Cosimi AB, Wee SL, Houser S, Andrews D, Sogawa H, Phelan J, Boskovic S, Nadazdin O, Abrahamian G, Colvin RB, Sach DH, Madsen JC. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation. 2002; 73: 1757–1764.[Medline] [Order article via Infotrieve]
32. Blom D, Morrissey NJ, Mesonero C, Coppage M, Fisher T, Zuo XJ, Jordan SC, Orloff MS. Induction of specific tolerance through mixed hematopoietic chimerism prevents chronic renal allograft rejection in a rat model. Surgery. 1996; 120: 213–219; discussion 219–220.[CrossRef][Medline] [Order article via Infotrieve]
33. Shirwan H, Wang HK, Barwari L, Makowka L, Cramer DV. Pretransplant injection of allograft recipients with donor blood or lymphocytes permits allograft tolerance without the presence of persistent donor microchimerism. Transplantation. 1996; 61: 1382–1386.[CrossRef][Medline] [Order article via Infotrieve]
34. Akyurek LM, Johnsson C, Lange D, Georgii-Hemming P, Larsson E, Fellstrom BC, Funa K, Tufveson G. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants: influence of Fas-mediated apoptosis. J Clin Invest. 1998; 101: 2889–2899.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  O. Dotsenko and M. Jahangiri Endogenous stem cells in patients undergoing coronary artery bypass graft surgery Eur. J. Cardiothorac. Surg., September 1, 2009; 36(3): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stamm, Y.-H. Choi, B. Nasseri, and R. Hetzer A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 215 - 229. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Suzuki, V. Iyer, T. Cimato, and J. M. Canty Jr Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133+ and cKit+ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle Circ. Res., January 30, 2009; 104(2): 255 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ziebart, C.-H. Yoon, T. Trepels, A. Wietelmann, T. Braun, F. Kiessling, S. Stein, M. Grez, C. Ihling, M. Muhly-Reinholz, et al. Sustained Persistence of Transplanted Proangiogenic Cells Contributes to Neovascularization and Cardiac Function After Ischemia Circ. Res., November 21, 2008; 103(11): 1327 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Reinecke, E. Minami, W.-Z. Zhu, and M. A. Laflamme Cardiogenic Differentiation and Transdifferentiation of Progenitor Cells Circ. Res., November 7, 2008; 103(10): 1058 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shimizu and R. N. Mitchell The Role of Chemokines in Transplant Graft Arterial Disease Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1937 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kerbel, R. Benezra, D. C. Lyden, K. Hattori, B. Heissig, D. J. Nolan, V. Mittal, Y. Shaked, S. Dias, F. Bertolini, et al. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas PNAS, August 26, 2008; 105(34): E54 - E54. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rupp, M. Koyanagi, M. Iwasaki, J. Bauer, S. von Gerlach, D. Schranz, A. M. Zeiher, and S. Dimmeler Characterization of long-term endogenous cardiac repair in children after heart transplantation Eur. Heart J., August 1, 2008; 29(15): 1867 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Surdacki, E. Marewicz, E. Wieteska, G. Szastak, T. Rakowski, E. Wieczorek-Surdacka, D. Dudek, J. Pryjma, and J. S. Dubiel Association between endothelial progenitor cell depletion in blood and mild-to-moderate renal insufficiency in stable angina Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2265 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Xu Stem Cells and Transplant Arteriosclerosis Circ. Res., May 9, 2008; 102(9): 1011 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schmauss and M. Weis Cardiac Allograft Vasculopathy: Recent Developments Circulation, April 22, 2008; 117(16): 2131 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lutz, M. Rosenberg, F. Kiessling, V. Eckstein, T. Heger, J. Krebs, A. D. Ho, H. A. Katus, and N. Frey Local injection of stem cell factor (SCF) improves myocardial homing of systemically delivered c-kit + bone marrow-derived stem cells Cardiovasc Res, January 1, 2008; 77(1): 143 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Muller, A. Kazakov, A. Semenov, M. Bohm, and U. Laufs Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells Cardiovasc Res, January 1, 2008; 77(1): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Nolan, A. Ciarrocchi, A. S. Mellick, J. S. Jaggi, K. Bambino, S. Gupta, E. Heikamp, M. R. McDevitt, D. A. Scheinberg, R. Benezra, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes & Dev., June 15, 2007; 21(12): 1546 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Mitchell and P. Libby Vascular Remodeling in Transplant Vasculopathy Circ. Res., April 13, 2007; 100(7): 967 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kolossov, T. Bostani, W. Roell, M. Breitbach, F. Pillekamp, J. M. Nygren, P. Sasse, O. Rubenchik, J. W. U. Fries, D. Wenzel, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium J. Exp. Med., October 2, 2006; 203(10): 2315 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kaye and M. D. Esler Letter by Kaye and Esler Regarding Article "Extracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heart" Circulation, June 6, 2006; 113(22): e844 - e844. [Full Text] [PDF]
|
|
|
|
|
|
E. Minami, M. A. Laflamme, C. E. Murry, and J. E. Saffitz Response to Letter Regarding Article "Extracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heart" Circulation, June 6, 2006; 113(22): e845 - e845. [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Murry, H. Reinecke, and L. M. Pabon Regeneration Gaps: Observations on Stem Cells and Cardiac Repair J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1777 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rafii and D. Lyden Contribution of Hematopoietic and Vascular Progenitor Cells to the Neoangiogenic Niche Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 181 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Esler and D. Kaye Sympathetic Nervous System Neuroplasticity Hypertension, February 1, 2006; 47(2): 143 - 144. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||